Literature DB >> 1528016

Genetic and clinical correlations of Xp21 muscular dystrophy.

K M Bushby1.   

Abstract

We have investigated over 100 patients with Xp21 muscular dystrophy, drawing together the results of detailed clinical, genetic and dystrophin investigations. A spectrum of disease severity was confirmed, with the most homogeneous clinical groups being at either end of the spectrum, represented by the typical Duchenne and Becker phenotypes. The groups in between showed clinical heterogeneity, and variability in the genetic and dystrophin results. While an out-of-frame deletion in association with undetectable dystrophin is most likely to predict the most severe phenotype, and increasing abundance of dystrophin is associated generally with a milder clinical course, no value of dystrophin abundance reliably predicts a particular phenotype. However, deletions of the dystrophin gene involving exons 45-47 and 45-48 especially do seem to be consistently associated with the mildest Becker phenotype. Additional factors must play a role in determining the exact clinical course.

Entities:  

Mesh:

Year:  1992        PMID: 1528016     DOI: 10.1007/bf01799614

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  34 in total

Review 1.  Genetics of Duchenne muscular dystrophy.

Authors:  R G Worton; M W Thompson
Journal:  Annu Rev Genet       Date:  1988       Impact factor: 16.830

2.  Prevalence and incidence of Becker muscular dystrophy.

Authors:  K M Bushby; M Thambyayah; D Gardner-Medwin
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

3.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

4.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities.

Authors:  K M Bushby; D Gardner-Medwin; L V Nicholson; M A Johnson; I D Haggerty; N J Cleghorn; J B Harris; S S Bhattacharya
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

5.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion.

Authors:  M Koenig; A H Beggs; M Moyer; S Scherpf; K Heindrich; T Bettecken; G Meng; C R Müller; M Lindlöf; H Kaariainen; A de la Chapellet; A Kiuru; M L Savontaus; H Gilgenkrantz; D Récan; J Chelly; J C Kaplan; A E Covone; N Archidiacono; G Romeo; S Liechti-Gailati; V Schneider; S Braga; H Moser; B T Darras; P Murphy; U Francke; J D Chen; G Morgan; M Denton; C R Greenberg; K Wrogemann; L A Blonden; M B van Paassen; G J van Ommen; L M Kunkel
Journal:  Am J Hum Genet       Date:  1989-10       Impact factor: 11.025

6.  Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody.

Authors:  L V Nicholson; K Davison; G Falkous; C Harwood; E O'Donnell; C R Slater; J B Harris
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

7.  Dystrophin or a "related protein" in Duchenne muscular dystrophy?

Authors:  L V Nicholson; M A Johnson; K Davison; E O'Donnell; G Falkous; M Barron; J B Harris
Journal:  Acta Neurol Scand       Date:  1992-07       Impact factor: 3.209

8.  Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history.

Authors:  M H Brooke; G M Fenichel; R C Griggs; J R Mendell; R Moxley; J P Miller; M A Province
Journal:  Muscle Nerve       Date:  1983-02       Impact factor: 3.217

9.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

10.  Dystrophin is transcribed in brain from a distant upstream promoter.

Authors:  F M Boyce; A H Beggs; C Feener; L M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more
  10 in total

1.  Genome-scan for IQ discrepancy in autism: evidence for loci on chromosomes 10 and 16.

Authors:  Nicola H Chapman; Annette Estes; Jeff Munson; Raphael Bernier; Sara J Webb; Joseph H Rothstein; Nancy J Minshew; Geraldine Dawson; Gerard D Schellenberg; Ellen M Wijsman
Journal:  Hum Genet       Date:  2010-10-21       Impact factor: 4.132

2.  Dp71f modulates GSK3-beta recruitment to the beta1-integrin adhesion complex.

Authors:  Joel Cerna Cortés; Eliud Alfredo Garcia Montalvo; Jesús Muñiz; Dominique Mornet; Efrain Garrido; Federico Centeno; Bulmaro Cisneros
Journal:  Neurochem Res       Date:  2008-08-02       Impact factor: 3.996

3.  Understanding adherence to noninvasive ventilation in youth with Duchenne muscular dystrophy.

Authors:  John E Pascoe; Hemant Sawnani; Brooke Hater; Mark Sketch; Avani C Modi
Journal:  Pediatr Pulmonol       Date:  2019-09-01

4.  Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.

Authors:  Isabelle Desguerre; Christo Christov; Michele Mayer; Reinhard Zeller; Henri-Marc Becane; Sylvie Bastuji-Garin; France Leturcq; Catherine Chiron; Jamel Chelly; Romain K Gherardi
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

5.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities.

Authors:  K M Bushby; D Gardner-Medwin; L V Nicholson; M A Johnson; I D Haggerty; N J Cleghorn; J B Harris; S S Bhattacharya
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

6.  Correlation between electroretinogram findings and molecular analysis in the Duchenne muscular dystrophy phenotype.

Authors:  I De Becker; D C Riddell; J M Dooley; F Tremblay
Journal:  Br J Ophthalmol       Date:  1994-09       Impact factor: 4.638

7.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

8.  Transgenic mdx mice expressing dystrophin with a deletion in the actin-binding domain display a "mild Becker" phenotype.

Authors:  K Corrado; J A Rafael; P L Mills; N M Cole; J A Faulkner; K Wang; J S Chamberlain
Journal:  J Cell Biol       Date:  1996-08       Impact factor: 10.539

9.  Gastrointestinal Dysfunction in Patients with Duchenne Muscular Dystrophy.

Authors:  Christian M Lo Cascio; Oliver Goetze; Tsogyal D Latshang; Sena Bluemel; Thomas Frauenfelder; Konrad E Bloch
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

10.  The relationship between scoliosis and upper extremity functions in patients with Duchenne muscular dystrophy.

Authors:  Nihan Erdinç Gündüz; Filiz Meryem Sertpoyraz; Banu Dilek; Ebru Şahin; Figen Baydan; Bedile İrem Tiftikcioglu; Elif Keskin Pehlivan; Aylin Dikici; Yaşar Zorlu; Elif Akalın; Özlen Peker
Journal:  Turk J Phys Med Rehabil       Date:  2021-03-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.